[Panel 2] Section 101, Mayo & Myriad and laws of nature

Friday, June 28, 2019 - 10:45am to 12:00pm
Panel Description: 

Progress in health sciences is affected by the Supreme Court's cases on eligibility, particularly Mayo and Myriad. Investments in biopharma inventions and discoveries, which typically must be enormous, may not be made at all, and therefore prevention, detection and cures not developed as a result of the present uncertainty. Lower courts have failed to provide clarity to the high court's cases, making venture capitalists and other potential investors hesitant. The same is true for corporate executives. Consequently, the potential of major breakthroughs in genetic engineering, personalized medicine and computer-related health invention using artificial intelligence may be precluded. Possible solutions will be discussed as well as comparisons to the wider eligibility available in other nations.


Crowell & Moring LLP

Washington, DC, USA

Dialogue Leaders

ExploraMed Development, LLC

Mountain View, CA, USA

Bristol-Meyer Squibb Company

Princeton, NJ, USA

Sterne, Kessler, Goldstein & Fox PLLC

Washington, D.C., USA

Rothwell, Figg, Ernst & Manbeck, P.C.

Washington, DC, USA

Teva Pharmaceuticals

Parsippany, NJ, USA